iHeart Japan Corporation

9:00 AM - 9:15 AM (JST), Wednesday, March 6, 2019 ・ 2nd Floor
Developing an allogeneic regenerative medicinal product for severe heart failure, which is made from iPS cell.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
IHJ-301: allogeneic regenerative medicine for heart failure
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):